摘要
经动脉化疗栓塞(transarterial chemoembolization,TACE)是治疗不能切除肝细胞癌(hepatocellularcarcinoma, HCC)的首选治疗方法,被证实能延长不能切除HCC患者的存活时间.然而,近期研究发现:TACE可能诱发HCC的乙肝病毒(hepatitis B virus,HBV)再激活, HBV-DNA大量复制,从而诱发HBV相关肝炎,甚至肝衰竭,导致HCC病人死亡,而术前应用抗病毒药物则可能降低术后HBV的再激活,改善病人的存活.本文将TACE对HCC-HBV再激活的影响及抗病毒药物对HBV再激活的抑制作用以及术后存活的影响进行综述.
Transarterial chemoembolization (TACE) is the first choice of treatment for unresectable hepatocellular carcinoma (HCC), which has been verified to prolong the survival times of patients with unresectable HCC. However, recent studies have reported that TACE might induce reactivation of hepatitis B virus (HBV), which presents as the replication of HBV-DNA, and lead to HBV related hepatitis, hepatic failure, and even death. Preoperative use of antiviral drugs has been proposed to decrease the reactivation rate of HBV and improve the survival of HCC patients probably. In this review, we will discuss the above issues.
作者
周倩
周晓晴
张涛
Qian Zhou;Xiao-Qing Zhou;Tao Zhang(North Sichuan Medical College,Nanchong 637000,Sichuan Province,China;Department of Gastroenterology,Nanchong Central Hospital,Nanchong 637000,Sichuan Province,China)
出处
《世界华人消化杂志》
CAS
2019年第10期651-655,共5页
World Chinese Journal of Digestology
基金
四川省卫生和计划生育委员会,No.17PJ030~~
关键词
经动脉化疗栓塞术
肝癌
乙肝病毒再激活
抗病毒药物
Transarterial chemoembolization
Hepatocellular carcinoma
Hepatitis B virus reactivation
Anti-viral drugs